Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on July 20, 2026 reporting Item 8.01 (Other Events). FDA accepted DYNE-251’s BLA for DMD patients amenable to exon 51 skipping, advancing the candidate toward potential commercialization.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA accepted DYNE-251’s BLA for DMD patients amenable to exon 51 skipping, advancing the candidate toward potential commercialization
- Priority Review granted, with a PDUFA target action date of January 21, 2027
- Potential U.S. launch targeted for Q1 2027, conditional on FDA approval
- Key risks remain regulatory interpretation of clinical data and adequacy of cash resources through commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.